MARKET

CKPT

CKPT

Checkpoint Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.420
-0.010
-0.29%
Pre Market: 3.420 0 0.00% 04:09 01/27 EST
OPEN
3.460
PREV CLOSE
3.430
HIGH
3.500
LOW
3.350
VOLUME
200
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
1.050
MARKET CAP
232.16M
P/E (TTM)
-7.5447
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
5 Top Penny Stocks To Watch During January's Biotech Boom
Penny Stocks · 5d ago
Checkpoint Therapeutics initiated at Cantor with Overweight
Checkpoint Therapeutics ([[CKPT]] +8.2%) was initiated at Cantor Fitzgerald with an Overweight rating, PT $16.Analyst Jennifer Kim believes that the potential peak sales opportunity for cosibelimab is underappreciated.Quick look at
Seekingalpha · 6d ago
DJ Checkpoint Therapeutics Price Target Announced at $16.00/Share by Cantor Fitzgerald
Dow Jones · 6d ago
DJ Checkpoint Therapeutics Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 6d ago
--Analyst Actions: Cantor Fitzgerald Starts Checkpoint Therapeutics at Overweight With $16 Price Target
MT Newswires · 01/20 08:25
Checkpoint Therapeutics to Participate in Three January 2021 Virtual Investor Conferences
Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in three virtual investor conferences in...
GlobeNewswire · 01/06 13:33
Checkpoint Therapeutics to Participate in Three January 2021 Virtual Investor Conferences
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will particip...
GlobeNewswire · 01/06 13:30
Checkpoint Therapeutics launches $100M ATM equity offering
Checkpoint Therapeutics (CKPT) entered into an equity distribution agreement dated December 17, 2020, providing for an at-the-market ("ATM") equity offering program, pursuant to a controlled equity offering  sales agreement between the Company, Cantor
Seekingalpha · 12/18/2020 13:38
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CKPT. Analyze the recent business situations of Checkpoint Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CKPT stock price target is 17.67 with a high estimate of 20.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 68
Institutional Holdings: 13.00M
% Owned: 19.15%
Shares Outstanding: 67.88M
TypeInstitutionsShares
Increased
20
1.82M
New
14
4.09M
Decreased
11
84.18K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/Director
Michael Weiss
President/Chief Executive Officer/Director
James Oliviero
Chief Financial Officer/Vice President - Finance/Secretary
William Gray
Director
Lindsay Rosenwald
Independent Director
Christian Bechon
Independent Director
Scott Boilen
Independent Director
Neil Herskowitz
Independent Director
Barry Salzman
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About CKPT
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.

Webull offers kinds of Checkpoint Therapeutics Inc stock information, including NASDAQ:CKPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CKPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CKPT stock methods without spending real money on the virtual paper trading platform.